Valuation : enGene Therapeutics Inc.

Market Cap 129M 111M 104M 94.94M 177M 12.19B 178M 1.23B 477M 6.23B 483M 472M 19.83B P/E 2026 *
-1.05x
P/E 2027 * -1.23x
Enterprise Value -82.63M -71.05M -66.84M -61M -114M -7.83B -114M -792M -306M -4B -310M -304M -12.74B EV / Sales 2026 *
-
EV / Sales 2027 * -2.55x
Free-Float
99.9%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : enGene Therapeutics Inc.

1 day-0.55%
1 week-1.89%
Current month-1.09%
1 month+1.11%
3 months+10.30%
6 months-79.03%
Current year-79.84%
1 week 1.78
Extreme 1.78
1.94
1 month 1.66
Extreme 1.66
1.95
Current year 1.4
Extreme 1.4
12.25
1 year 1.4
Extreme 1.4
12.25
3 years 1.4
Extreme 1.4
47.17
5 years 1.4
Extreme 1.4
47.17
10 years 1.4
Extreme 1.4
47.17
Manager TitleAgeSince
Chief Executive Officer 63 22/07/2024
Chief Tech/Sci/R&D Officer 55 24/04/2023
Director of Finance/CFO 48 16/07/2026
Director TitleAgeSince
Director/Board Member 57 08/08/2023
Director/Board Member 66 18/12/2023
Director/Board Member 66 15/05/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/7/26 Other

Interim Chief Business Officer

75,000 0.1120%
16/7/26 Other

Chief Financial Officer

0 0%
16/7/26 Other

Chief Financial Officer

170,800 0.2550%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-1.89%-66.48%-83.30% 122M
+2.02%+1.26%+41.37%+105.18% 67.82B
-0.41%-2.30%+33.53%+78.63% 63.22B
-1.11%+2.78%-14.86%+375.59% 27.58B
-4.92%-3.22%-3.90%-17.87% 26.06B
+0.37%+0.41%+31.28%+15.78% 25.38B
+1.12%+0.84%+24.50%-17.84% 19.89B
+6.04%+7.25%+233.25%+383.12% 17.4B
+0.57%-0.61%-6.40%+527.40% 14.95B
-2.27%+1.37%+53.01%+160.83% 14.62B
Average +0.06%+0.91%+32.53%+152.75% 27.71B
Weighted average by Cap. +0.22%+0.44%+37.63%+140.54%

Financials

2026 *2027 *
Net sales - 7.05M 6.06M 5.7M 5.21M 9.71M 669M 9.76M 67.59M 26.15M 342M 26.48M 25.9M 1.09B
Net income -126M -108M -102M -92.93M -173M -11.93B -174M -1.21B -467M -6.1B -473M -462M -19.41B -122M -105M -98.59M -89.97M -168M -11.56B -169M -1.17B -452M -5.91B -458M -448M -18.8B
Net Debt -211M -182M -171M -156M -291M -20.03B -293M -2.02B -783M -10.24B -793M -776M -32.57B -147M -126M -119M -108M -202M -13.9B -203M -1.41B -544M -7.11B -551M -539M -22.61B
Logo enGene Therapeutics Inc.
enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
Employees
-
Date Price Change Volume
08/09/26 US$1.920 +5.49% 1,508,311
04/09/26 US$1.820 -0.55% 412,684
03/09/26 US$1.830 -3.17% 634,651
02/09/26 US$1.890 +1.89% 1,061,722
01/09/26 US$1.855 +0.82% 657,377
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
1.920USD
Average target price
3.286USD
Spread / Average Target
+71.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ENGN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!